PSTX
Income statement / Annual
Last year (2023), Poseida Therapeutics, Inc.'s total revenue was $64.70 M,
a decrease of 50.37% from the previous year.
In 2023, Poseida Therapeutics, Inc.'s net income was -$123.43 M.
See Poseida Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
Operating Revenue |
$64.70 M
|
$130.36 M
|
$31,238.00
|
$0.00
|
$0.00
|
$0.00
|
$2.99 M
|
$9.77 M
|
Cost of Revenue |
$5.61 M |
$5.17 M |
$4.55 M |
$2.59 M |
$1.19 M |
$689,000.00 |
$0.00 |
$0.00 |
Gross Profit |
$59.09 M |
$125.19 M |
-$4.52 M |
-$2.59 M |
-$1.19 M |
-$689,000.00 |
$2.99 M |
$9.77 M |
Gross Profit Ratio |
0.91 |
0.96 |
-144.72 |
0 |
0 |
0 |
1 |
1 |
Research and Development
Expenses |
$156.77 M
|
$152.90 M
|
$136,734.00
|
$103,520.00
|
$60.39 M
|
$30.88 M
|
$19.10 M
|
$9.86 M
|
General & Administrative
Expenses |
$37.44 M
|
$37.54 M
|
$35,915.00
|
$23,029.00
|
$18.46 M
|
$9.67 M
|
$5.48 M
|
$5.35 M
|
Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$220,000.00
|
Selling, General &
Administrative Expenses |
$37.44 M
|
$37.54 M
|
$35,915.00
|
$23,029.00
|
$18.46 M
|
$9.67 M
|
$5.48 M
|
$5.13 M
|
Other Expenses |
$14.85 M |
$2.86 M |
$19,795.00 |
$280.00 |
$2.56 M |
-$821,000.00 |
$37,000.00 |
$0.00 |
Operating Expenses |
$194.21 M |
$190.44 M |
$172,649.00 |
$126,549.00 |
$78.85 M |
$40.56 M |
$24.58 M |
$15.00 M |
Cost And Expenses |
$194.21 M |
$190.44 M |
$172,649.00 |
$126,549.00 |
$78.85 M |
$40.56 M |
$24.58 M |
$15.22 M |
Interest Income |
$0.00 |
$6.37 M |
$3.36 M |
$3.51 M |
$1.55 M |
$0.00 |
$0.00 |
$0.00 |
Interest Expense |
-$8.67 M |
$6.37 M |
$3,358.00 |
$3,506.00 |
$3.55 M |
$1.80 M |
$558,000.00 |
$0.00 |
Depreciation &
Amortization |
$5.61 M
|
$5.17 M
|
$4.55 M
|
$2.59 M
|
$1.19 M
|
$689,000.00
|
$676,000.00
|
$220,000.00
|
EBITDA |
-$129.50 M
|
-$57.09 M
|
-$121,616.00
|
-$126,269.00
|
-$75.10 M
|
-$40.69 M
|
-$20.88 M
|
-$5.23 M
|
EBITDA Ratio |
-2 |
-0.44 |
-3.89 |
0 |
0 |
0 |
-6.99 |
-0.54 |
Operating Income Ratio
|
-2
|
-0.46
|
-4.53
|
0
|
0
|
0
|
-6.59
|
-0.56
|
Total Other
Income/Expenses Net |
$6.18 M
|
-$3.51 M
|
$16,437.00
|
-$3,226.00
|
-$994,000.00
|
-$2.25 M
|
$1.96 M
|
$109,000.00
|
Income Before Tax |
-$123.32 M |
-$63.46 M |
-$124,974.00 |
-$129,775.00 |
-$86.53 M |
-$44.61 M |
-$20.19 M |
-$5.34 M |
Income Before Tax Ratio
|
-1.91
|
-0.49
|
-4
|
0
|
0
|
0
|
-6.76
|
-0.55
|
Income Tax Expense |
-$107,000.00 |
$544,000.00 |
-$4.53 M |
-$2.58 M |
$6.11 M |
-$202,000.00 |
-$527,000.00 |
-$765,000.00 |
Net Income |
-$123.43 M |
-$64.00 M |
$4.40 M |
$2.45 M |
-$92.64 M |
-$44.40 M |
-$19.66 M |
-$4.58 M |
Net Income Ratio |
-1.91 |
-0.49 |
140.98 |
0 |
0 |
0 |
-6.59 |
-0.47 |
EPS |
-1.37 |
-0.89 |
0.0708 |
0.0681 |
-2.33 |
-1.24 |
-0.49 |
-0.0771 |
EPS Diluted |
-1.37 |
-0.89 |
0.0708 |
0.0681 |
-2.33 |
-1.24 |
-0.49 |
-0.0771 |
Weighted Average Shares
Out |
$90.19 M
|
$71.91 M
|
$62.18 M
|
$36.00 M
|
$39.73 M
|
$35.93 M
|
$39.73 M
|
$59.32 M
|
Weighted Average Shares
Out Diluted |
$90.19 M
|
$71.95 M
|
$62.24 M
|
$36.00 M
|
$39.73 M
|
$35.93 M
|
$39.73 M
|
$59.32 M
|
Link |
|
|
|
|
|
|
|
|